期刊文献+

奥曲肽抑制肝癌切除术后复发转移的研究 被引量:4

Effect of octreotide on recurrence and metastasis of hepatocellular carcinoma after curative resection in nude mice
原文传递
导出
摘要 目的 探讨奥曲肽对裸鼠肝癌切除术后复发转移的抑制作用。方法 应用LCI D2 0裸鼠人肝癌转移模型 ,于种植后第 10天行肝癌切除术 ,采用不同剂量的奥曲肽治疗 ,观察肿瘤肝内复发、肝外转移情况。采用LCI D2 0裸鼠角膜微囊移植模型 ,观测奥曲肽对肝癌诱导肿瘤血管形成能力的影响。结果 对照组肺转移率、肝内复发率为 10 0 % ,复发癌灶体积为 ( 1164 .7± 471.3 )mm3;10 0 μg/kg治疗组则分别为 40 %、60 %、( 81.5± 17.1)mm3;2 0 0 μg/kg治疗组则分别为 0、40 %、( 9.0± 6.8)mm3。奥曲肽可明显抑制LCI D2 0肝癌组织诱导的角膜新生血管形成。结论 奥曲肽能抑制高转移性人肝癌切除术后的复发转移 ,并呈量效关系 ;抑制肝癌新生血管形成可能是其作用机制之一。 Objective To investigate the effect of octreotide on recurrence and metastasis of hepatocellular carcinoma (HCC) after curative resection in nude mice.Methods The metastatic model of human HCC in nude mice LCI-D20 and LCI-D20 corneal micropocket model were established.MTT assay was used to investigate the effect of octreotide on human HCC cells.Results The lung metastatic rate,the liver recurrent rate and the size of the recurrent tumor was 100%,100% and (1?164.7±471.3) mm3 in the untreated control group respectively,whereas 40%,60% and (81.5±17.1) mm3 in the octreotide 100 μg·kg -1·d -1 treated group respectively (P<0.05),and 0,40% and (9.0±6.8) mm3 in the octreotide 200 μg·kg -1·d -1 treated group respectively (P<0.01).Octreotide could markedly suppress nude mice corneal neovascularization induced by LCI-D20 tumor.Conclusion Octreotide could dose-dependently inhibit recurrence and metastasis of HCC after curative resection in nude mice.The effect of octreotide may be mediated by inhibiting angiogenesis induced by HCC in this experiment.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2003年第7期624-625,T002,共3页 Chinese Journal of Experimental Surgery
基金 安徽省自然科学基金安科医药专项资助项目( 0 10 4 370 8)
关键词 奥曲肽 肝癌 切除术 术后 肿瘤复发 肿瘤转移 Carcinoma,hepatocelluar Angiogenesis Metastasis Octreotide
  • 相关文献

同被引文献28

  • 1XinLi Gan-ShengFeng Chuan-ShengZheng Chen-KaiZhuo XiLiu.Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J].World Journal of Gastroenterology,2004,10(19):2878-2882. 被引量:54
  • 2王磊,刘海林,霍立.生长抑素受体亚型介导人肝癌细胞凋亡的实验研究[J].肿瘤,2005,25(3):232-235. 被引量:2
  • 3Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival [ J ]. Hepatology,2003,37 ( 2 ) :429 - 442.
  • 4E Kouroumalis, P Skordilis, K Thermos, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study [ J ]. Gut, 1998,42:442 - 447.
  • 5Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost, 2001, 86:23-33.
  • 6Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi' s sarcoma tumor growth through inhibition of angiogenesis. FASEB J,1999, 13: 647-655.
  • 7Dasgupta P, Mukherjee R. Lipophilization of somatostatin analog RC160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. Br J Pharmacol, 2000, 129:101-109.
  • 8Foekens JA;Peters HA;Look MP.The urokinase system of plasminogen activation and prognosisin 2780 breast cancer patients,2000.
  • 9Suzuki N;Fujioka K;Denda-Nagai K.The macrophage C-type lectin specific for galactose/N-acety lgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells[J],2002(23).
  • 10Ogata R;Torimura T;Kin M.Increase depression of membrane type 1 oproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinoma (see comments),1999.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部